key: cord-0950856-ujbtwlht
authors: nan
title: To the Editor
date: 2021-05-30
journal: Nutrition
DOI: 10.1016/j.nut.2021.111361
sha: 4bdade8e133fc0ce39906c02a7a8ed84a32ce091
doc_id: 950856
cord_uid: ujbtwlht

nan

We greatly appreciate the comments raised by Speeckaert & Delanghe that recommend to include data on polymorphism of vitamin D binding protein (DB) as a potential risk factors in patients with lower levels of vitamin D, in addition to other comorbidities such as obesity, cardiovascular, diabetes and respiratory diseases. All are known risk factors associated with severity and mortality related to COVID-19 infection.

Their studies demonstrated worse outcomes in COVID 19 patients with vitamin D deficiency in carriers of the DBP2 haplotype (1) . The authors should be commended for their research as it may fit into the notion of "personal medicine" and potentially account for the racial differences associated with vitamin D deficiency and morbidity related to COVID 19.

In a previous study when black Americans were compared with whites, they had lower levels of total 25hydroxyvitamin D and vitamin D-binding protein but had a similar concentration of estimated bioavailable 25-hydroxyvitamin D. The authors concluded that "racial differences in the prevalence of common genetic polymorphisms may provide a likely explanation for this observation" (2) .

Although the "free hormone hypothesis" stipulates that only free and unbound vitamin D can make a cellular entry, there is some evidence that DPB bound vitamin D can signal through some cells as well (3) . DBP is genetically very polymorphic with three frequent alleles (DBP/GC 1f, 1s, and 2) but with more than 120 different variants with heath impacts far from completely understood. In addition, there is no standardization of the polymorphism assays (3). When DBP assays were validated by mass spectrometric methods that are considered to be more sensitive and specific than immunoassays for the quantification of proteins in human samples, the DBG levels did not vary by race, counter to prior observations by immunoassays (4).

While the use of pharmacogenomics in research is completely justified especially in the face of a pandemic, the lack of detailed information on DBP biological activities and the lack of prospective longitudinal studies may hinder the use of the data for the clinical care of COVID 19 patients.

It seems that DBP polymorphism assays at this time may fit into an elective care framework when vitamin D deficiency is being investigated and treated properly. It is premature to introduce this concept in an acute care and ICU hospital setup where Vitamin D is not the focus of the treatment.

In conclusion, assays standardization and better understanding of the DBG polymorphism are crucial before this information can be assessed in a hospital and used clinically at the patient's bedside in an acute COVID19 setup.

Vitamin D binding protein polymorphism and COVID-19

Vitamin D-binding protein and vitamin D status of black Americans and white Americans

Vitamin D Binding Protein: A Historic Overview

Measurement by a Novel LC-MS/MS Methodology Reveals Similar Serum Concentrations of Vitamin D-Binding Protein in Blacks and Whites